A phase I open-label safety and pharmacokinetic study of escalating doses of SGT-53 for infusion in subjects with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs SGT 53 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors SynerGene Therapeutics
- 24 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 14 Sep 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.